Glycosylated Ferritin in Differential Diagnosis of Still's Disease, Sepsis and Other Macrophagic Activation Syndromes

What this Trial Is About

Researchers are studying the role of glycosylated ferritin in helping to diagnose adult Still's disease, haemophagocytosis lymphohistiocytic syndromes (HLH), sepsis, and other macrophagic activation syndromes. These conditions can be challenging to distinguish because they share similar symptoms and inflammation patterns. Glycosylated ferritin levels, especially when below 20%, may indicate these diseases and are part of diagnostic criteria, but interpretation can be complicated by conditions like severe liver damage or sepsis. This observational study collects serum samples from adults suspected of having HLH syndrome or Still's disease, as well as from control groups with sepsis, inflammation, liver damage, or hematologic malignancies. The study analyzes the glycosylation patterns of ferritin using mass spectrometry to evaluate its diagnostic performance and to explore differences among patient subgroups based on clinical and biological markers. Participants will provide blood samples for glycosylated ferritin testing and undergo clinical evaluations including fever, organ enlargement, blood counts, liver enzymes, and inflammatory markers. Researchers will monitor these measurements over one year to assess the fraction of glycosylated ferritin in serum. The study aims to better characterize the diagnostic value of ferritin glycosylation and improve differentiation between these complex inflammatory conditions.

Glycosylated Ferritin in Macrophagic Activation Syndromes